Complete Growth Overview on Generic Injectables Industry

Hospira was a global American pharmaceutical and medical device company headquartered in Lake Forest, Illinois. It had approximately 19,000 employees. Prior to its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute care and oncology injectables, as well as integrated infusion therapy and drug management systems. Hospira products are used by hospitals and alternative site providers, such as clinics, home care providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, which subsequently sold the medical device portion of Hospira to ICU Medical.

Get Sample PDF

Some of the key players of Generic Injectables Industry:

Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma, Endo International PLC

In January 2004, Abbott announced the split of its hospital products division. Hospira's name was chosen by employee vote. The name is derived from the words hospital, spirit, inspire and the Latin word "spero", which means "hope". Hospira became an independent company on May 3, 2004, with 14,000 employees, 14 manufacturing sites and estimated annual sales of $ 2.5 billion.

In 2007, Hospira purchased Mayne Pharma Ltd., an Australian specialty injectable pharmaceutical company, for $ 2.1 billion. In 2009, Hospira acquired the biotechnology businesses of Pliva-Croatia, the injectable generic pharmaceutical business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceutical company, for approximately $ 400 million, and TheraDoc, a clinical informatics company that develops hospital monitoring systems, in 2009. In 2010, Hospira acquired Javelin Pharmaceuticals, Inc., maker of the postoperative pain management drug Dyloject, for approximately $ 145 million.